CBG Studies Show Anti-Viral Properties and More
Mar 31, 2020 02:53PM
By Amber McKenzie
by Michael Pickens
Although cannabis is a
complex plant with more than 400 chemical entities, the cannabis/hemp industry
has—for the most part—remained fixated on two particular cannabinoids: THC and
cannabidiol (CBD). However, other cannabinoids are starting to emerge into the
One of these so-called minor cannabinoids is cannabigerol (CBG), which is gaining attention for its proclaimed antibacterial, anti-microbial, anti-inflammatory and anti-viral properties. While CBG has yet to match the mainstream appeal of CBD, this cannabinoid may soon play a starring role in everyday consumer products as it quietly demonstrates a wide array of intriguing medicinal benefits.
“The pharmacological effects of CBG described in the scientific literature include: anti-fungal, anti-insect and anti-inflammatory activity; neuroprotective activity; stimulation of appetite, and enhancement of the death process of cancer cells,” reports Dr. Itzhak Kurek, CEO and co-founder of Cannformatics, a Northern California biotech company that uses bioinformatics to improve medical cannabis.
Following the passage of the 2018 Farm Bill, which legalized industrial hemp production and established a THC limit of 0.3 percent, the industry is starting to realize the potential value that CBG presents from a medicinal standpoint. However, over the last few decades, scientists have left a paper trail of research that shows just how fruitful this relatively unknown cannabinoid could be.